Through computational integration of clinical data and a rich spectrum of PCa genomic datasets4,5,8,9, including somatic mutation data from 200 primary10 and 101 metastatic PCa tumors11, functional AR enhancer activity mapping of 20,790 ARBS through massive parallel reporter assays12, enhancer CRISPR screening13, single-cell chromatin accessibility sequencing data from PCa cells14 and 3D-genome data5,14 (Supplementary Table 1), we deeply characterize the biological basis and consequences of AR enhancer heterogeneity in PCa and assess its clinical impact on patient metastatic progression. This evidence concerns the gene AR and posterior cortical atrophy.